RxDoctor Payments Data

Charmaine Blair, MD

Internal Medicine · Columbus, OHNPI 1740264647

Payments from drug & device makers

$1,903in general payments, 2019–2025

Across 100 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$421
  • AbbVie$253
  • Amgen$217
  • AstraZeneca$210
  • Pfizer$178
  • Astellas Pharma US Inc$127
  • plus $497 from 13 others

What the payments were for

  • Food & beverage$1,903100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,903 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$74,324
Medicare patients
146
Services billed
1,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$60,270
OzempicSemaglutide42$47,944
ProliaDenosumab14$23,404
TrulicityDulaglutide19$22,915
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,719
SymbicortBudesonide/Formoterol Fumarate33$14,470
JardianceEmpagliflozin11$10,564
JanuviaSitagliptin Phosphate13$10,535
Breo ElliptaFluticasone/Vilanterol16$7,783
LinzessLinaclotide11$6,859
LivaloPitavastatin Calcium11$6,302
Albuterol Sulfate HfaAlbuterol Sulfate55$2,655
Rosuvastatin Calcium173$2,219
Nebivolol Hcl22$1,784
Atorvastatin Calcium176$1,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$60,27071 claims
Novo NordiskOzempic$421$47,94442 claims
GSKTrelegy Ellipta, Breo Ellipta$40$26,50242 claims
AmgenProlia$217$23,40414 claims
Lilly USA, LLCTrulicity$31$22,91519 claims
AstraZenecaSymbicort$210$14,47033 claims
AbbVieLinzess, Synthroid$253$8,22924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →